218 related articles for article (PubMed ID: 29152786)
1. Neurocognitive performance after PCSK9 inhibitor therapy: Current state of the evidence.
Stamerra CA; Di Giosia P; Giorgini P; De Feo M; Grassi D; Ferri C; Sahebkar A
J Neurosci Res; 2018 May; 96(5):762-764. PubMed ID: 29152786
[No Abstract] [Full Text] [Related]
2. Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.
Fazio S; Robertson DG; Joh T; Wan H; Riel T; Forgues P; Baum CM; Garzone PD; Gumbiner B
Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29057618
[TBL] [Abstract][Full Text] [Related]
3. The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies.
Gumbiner B; Joh T; Liang H; Wan H; Levisetti M; Vana AM; Shelton DL; Forgues P; Billotte S; Pons J; Baum CM; Garzone PD
Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29078037
[TBL] [Abstract][Full Text] [Related]
4. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk.
Milionis H; Barkas F; Ntaios G; Papavasileiou V; Vemmos K; Michel P; Elisaf M
Eur J Intern Med; 2016 Oct; 34():54-57. PubMed ID: 27363304
[TBL] [Abstract][Full Text] [Related]
5. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial.
Katsiki N; Athyros VG; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Sep; 74():43-46. PubMed ID: 28477848
[No Abstract] [Full Text] [Related]
6. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
7. PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes.
Hess CN; Low Wang CC; Hiatt WR
Annu Rev Med; 2018 Jan; 69():133-145. PubMed ID: 29095667
[TBL] [Abstract][Full Text] [Related]
8. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
[TBL] [Abstract][Full Text] [Related]
9. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
Della Badia LA; Elshourbagy NA; Mousa SA
Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
[TBL] [Abstract][Full Text] [Related]
10. Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease.
Wójcik C
Postgrad Med; 2017 Nov; 129(8):801-810. PubMed ID: 28879791
[TBL] [Abstract][Full Text] [Related]
11. [Inhibitors of PCSK9].
Petrova-Slater I; Denegri A; Pasotti E; Rossi MG; Spirk D; Riesen WF; Moccetti T; Moccetti M
Rev Med Suisse; 2017 Apr; 13(558):821-825. PubMed ID: 28727332
[TBL] [Abstract][Full Text] [Related]
12. [PCSK9 inhibitors in hypercholesterolemia. New hope for patients with diabetes mellitus?].
Parhofer KG
Herz; 2016 May; 41(3):217-23. PubMed ID: 26961236
[TBL] [Abstract][Full Text] [Related]
13. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.
Wan H; Gumbiner B; Joh T; Riel T; Udata C; Forgues P; Garzone PD
Clin Ther; 2017 Nov; 39(11):2243-2259.e5. PubMed ID: 29037448
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials.
Kereiakes DJ; Lepor NE; Gerber R; Veronica Lee L; Elassal J; Thompson D; Michael Gibson C
Atherosclerosis; 2018 Oct; 277():211-218. PubMed ID: 30025648
[TBL] [Abstract][Full Text] [Related]
15. PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option.
Pokrywka GS
Postgrad Med; 2018 Apr; 130(3):287-298. PubMed ID: 29411675
[TBL] [Abstract][Full Text] [Related]
16. Inconsistent Guideline Recommendations for Cardiovascular Prevention and the Debate About Zeroing in on and Zeroing LDL-C Levels With PCSK9 Inhibitors.
Ioannidis JPA
JAMA; 2017 Aug; 318(5):419-420. PubMed ID: 28738115
[No Abstract] [Full Text] [Related]
17. Transient ischaemic attack after spacing the dose of alirocumab: Is it advisable to reduce the doses of PCSK9 inhibitors with very low LDL-cholesterols?
Piqueras Ruiz S; Parra Virto A; Torres do Rego A; Demelo Rodríguez P; Álvarez-Sala Walther L
Clin Investig Arterioscler; 2020; 32(1):30-32. PubMed ID: 31221533
[TBL] [Abstract][Full Text] [Related]
18. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.
Nissen SE; Dent-Acosta RE; Rosenson RS; Stroes E; Sattar N; Preiss D; Mancini GB; Ballantyne CM; Catapano A; Gouni-Berthold I; Stein EA; Xue A; Wasserman SM; Scott R; Thompson PD;
Clin Cardiol; 2016 Mar; 39(3):137-44. PubMed ID: 26946077
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Hypercholesterolemia in 2015.
Aronow WS
Am J Ther; 2017; 24(2):e121-e129. PubMed ID: 26422823
[TBL] [Abstract][Full Text] [Related]
20. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?
Banach M; Penson PE
Cardiovasc Res; 2019 Mar; 115(3):e26-e31. PubMed ID: 30605511
[No Abstract] [Full Text] [Related]
[Next] [New Search]
